Article
Allergan begins launch of cyclosporine
Irvine, CA-In early April, cyclosporine ophthalmic emulsion 0.05% (Restasis, Allergan) became commercially available for the treatment of eye inflammation associated with keratoconjunctivitis sicca. The introduction of the product marks the first therapeutic option for people with dry eye by not only providing temporary relief of dry eye, but also treating the associated ocular inflammation, according to the company.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
